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Abstract
Objective: Few studies have determined the effects of more than 5–10 years of GH replacement in adults
on bone mineral content (BMC) and bone mineral density (BMD).
Design/patients: In this prospective, single-centre, open-label study, the effects of 15 years of GH
replacement on BMC and BMD, measured using dual-energy X-rayabsorptiometry, were determined in
126 hypopituitary adults (72 men) with adult-onset GH deﬁciency (GHD). Mean age was 49.4 (range
22–74) years at the initiation of the study.
Results: The mean initial GH dose of 0.63 (S.E.M. 0.03) mg/day was gradually lowered to 0.41 (0.01)
mg/day after 15 years. The mean serum IGF1 SDS increased from K1.69 (0.11) at baseline to 0.63
(0.16) at the study end (P!0.001 vs baseline). The 15 years of GH replacement induced a sustained
increase in total body BMC (C5%, P!0.001) and BMD (C2%, P!0.001). Lumbar (L2–L4) spine
BMC increased by 9% (P!0.001) and BMD by 5% (P!0.001). In femur neck, a peak increase in BMC
and BMD of 7 and 3%, respectively, was observed after 7 years (both P!0.001). After 15 years, femur
neck BMC was 5% above the baseline value (P!0.01), whereas femur neck BMD had returned to the
baseline level. In most variables, men had a more marked response to GH replacement than women.
Conclusions: Fifteen-year GH replacement in GHD adults induced a sustained increase in total body and
lumbar (L2–L4) spine BMC and BMD. In femur neck, BMC and BMD peaked at 7 years and then
decreased towards baseline values.
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Introduction
Young adults with GH deﬁciency (GHD) have reduced
bone mineral content (BMC) and bone mineral density
(BMD) (1, 2, 3, 4). This reduction in BMC and BMD is
more marked in patients with childhood-onset (CO)
GHD than in patients with adult-onset (AO) GHD (5).
Elderly GHD adults do not have a reduced bone mass
and density compared with age-matched healthy
controls (6, 7). However, adult GHD patients without
GH replacement are at a higher risk of fractures than
healthycontrols of the same age(8, 9, 10). It is therefore
possible that other factors than reduced BMD, such as
increased number of falls due to visual deﬁcits caused by
pituitary tumours or their treatment, could contribute
to the increased fracture risk in GHD adults.
Initiation of GH replacement in adults with GHD
induces an initial increase in bone resorption that may
result in unchanged or even reduced bone mass (2, 3).
This is followed by increased bone formation and a net
increase in bone mass seen after 12–18 months of
GH replacement (2, 3). GH exerts direct effects on bone
(2, 11), but it has been questioned whether the direct
effects can fully explain the effects of GH on bone.
Indirect effects, such as increased muscle performance
by GH, could also be of importance (12). Furthermore,
the responsiveness to GH replacement is dependent on
the group of patients studied. The increase in BMC and
BMD is larger in patients with CO GHD compared with
patients with AO GHD (5) and also more marked in men
compared with women (13, 14, 15, 16, 17, 18). Finally,
the response to GH is most marked at weight-bearing
locations and the increase in BMC is greater than that of
BMD (15, 17).
GH replacement has been shown to induce a
progressive increase in bone mass and density up to
5–6 years of treatment (15, 19, 20, 21). One study of 7
years of GH replacement showed an increase in BMC
and BMD up to 4 years and after that BMC and BMD
reached a plateau (13). In another study, total body and
lumbar (L2–L4) spine BMD and BMC increased
progressively up to 10 years of GH replacement,
whereas femur neck BMC and BMD reached a peak
value after 5–7 years of treatment (22).
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replacement may therefore continue over decades.
Long-term studies on the effects of GH treatment are
therefore important. There are at present no studies of
more than 10 years of GH replacement. The aim of this
study was to investigate the effects of 15 years of GH
replacement therapy on BMC and BMD in patients with
AO GHD recruited at a single centre.
Patients and methods
Patients
In this study, 126 consecutive GHD adults (72 men)
with a mean age of 49.4 (range 22–74) years were
included between 1990 and 1994. All patients had AO
pituitary disease and all had known pituitary disease or
other anterior pituitary hormonal deﬁciencies. The
pituitary deﬁciency was mainly caused by pituitary
tumours and/or their treatment (Tables 1 and 2). The
patients had been treated with pituitary surgery
(nZ49), surgery and radiotherapy (nZ49), radio-
therapy alone (nZ11) and no treatment (nZ17).
Most patients had multiple anterior pituitary hormo-
nal deﬁciencies (Tables 1 and 2). Possibly due to late
effects of radiotherapy, several patients had more
pituitary hormonal deﬁciencies at study end compared
with baseline (Tables 1 and 2). In 116 of the patients,
the diagnosis of GHD was based on a peak GH !3 mg/l
during a stimulation test (insulin (nZ112), GHRH
(nZ2) and glucagon (nZ2)). In nine patients, the
diagnosis was based on a 24-h GH proﬁle (sampling
every 30 min). In one patient, who had a known
anterior pituitary disease and three additional hormo-
nal deﬁciencies, the diagnosis was based on a low serum
insulin-like growth factor 1 (IGF1) level. When
required, patients received adequate and stable therapy
with glucocorticoids, thyroid hormone and desmopres-
sin. All the testosterone-deﬁcient men received tes-
tosterone therapy. However, at baseline 52% (25 out of
48) and at study end 31% (15 out of 48) of the
oestrogen-deﬁcient women received oestrogen replace-
ment therapy. Five patients received treatment with
vitamin D, calcium and/or bisphosphonates after 5
(nZ1), 11 (nZ1) and 13 (nZ3) years of GH
replacement. In these patients, the measurements
performed after the initiation of treatment with vitamin
D, calcium and/or bisphosphonates were excluded in
the statistical analysis, and the last value before
treatment was carried forward according to the
intention-to-treat approach used.
Fourteen of the patients died during the study period
(cerebral infarction (nZ3 ) ,m y o c a r d i a li n f a r c t i o n
(nZ2), pneumonia (nZ2), sudden death of unknown
cause (nZ1), renal cancer (nZ1), subarachnoid
haemorrhage (nZ1), chronic obstructive pulmonary
disease (nZ1), perimyocarditis (nZ1), pulmonary
embolism (nZ1) and coronary artery disease (nZ1)).
Fourteen patients discontinued GH replacement (lack of
compliance (nZ7), old age (nZ3), colon cancer (nZ1),
epilepsy after stroke (nZ1), pulmonary cancer (nZ1)
and chronic lymphocytic leukaemia (nZ1)). Eight
patients were lost to follow-up because they moved to
other cities or abroad. Thus, 90 of the 126 patients
completed the 15 years of GH replacement. All patients
were, however, retained in the statistical analysis
according to the intention-to-treat approach used.
Study protocol
This is an ongoing, prospective, open-label treatment
trial. The ﬁrst 64 patients initially received a weight-
based GH dose of 11.9 mg/kg per day (0.25 IU/kg per
week). During the ﬁrst 2–3 years of treatment, the GH
dose was gradually lowered and individualised when
the weight-based dose regimen was abandoned. In the
remaining 62 patients, the dose of GH was individua-
lised from the initiation of the treatment, with the aim of
normalising serum IGF1 concentration and body
composition in each patient.
At baseline, and after each year of GH replacement
until 5 years, and then after 7, 10, 12 and 15 years,
physical and laboratory including measurements of
bone mass examinations were performed. Dose titration
Table 1 Causes of pituitary deﬁciency in the study population of
126 adults with adult-onset GH deﬁciency.
Causes of pituitary
deﬁciency Men (n) Women (n) Total (n)
Pituitary adenoma
Non-secreting 44 22 66
Secreting 11 13 24
Craniopharyngioma 7 6 13
Empty sella 3 4 7
Sheehan’s syndrome 0 3 3
Idiopathic 0 2 2
Other pathology
a 741 1
Total 72 54 126
aOne patient with a meningioma, two with pituitary apoplexia, one with
histiocytosis X, two with sarcoidosis, one with a cholesteatoma, one with an
ependymoma, one with a dysgerminoma and two with trauma.
Table 2 Number of pituitary deﬁciencies at baseline and after 15
years of GH replacement (study end) in the study population of 126
adults with adult-onset GH deﬁciency (GHD).
Baseline (n) Study end (n)
Type of
deﬁciency Men Women Total Men Women Total
Isolated GHD 7 2 9 3 1 4
No. of additional
deﬁciencies
17 9 1 6 1 7 8
2 10 8 18 14 6 20
34 8 3 5 8 3 5 4 4 0 9 4
Diabetesinsipidus 22 15 37 23 18 41
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month during the ﬁrst year and every sixth month
thereafter. Body weight was measured in the morning
to the nearest 0.1 kg and body height was measured to
the nearest 0.01 m. Body mass index (BMI) was
calculated as the weight in kilograms divided by the
height in meters squared. No effort was made to
inﬂuence the patients’ physical activity level during
the study period.
Ethical considerations
Informed consent was obtained from all patients. The
study was approved by the Regional Ethics Review
Board at the University of Gothenburg and the Swedish
Medical Products Agency (Uppsala, Sweden).
BMC and BMD
BMC and BMD were measured by dual-energy X-ray
absorptiometry (DXA) in the total body, lumbar spine
and femur neck as described previously (23). From the
initiation of the study until the end of 1999, a LUNAR
DPX-L scanner was used (Scanex, Helsingborg, Swe-
den). Software versions were changed several times
(from 1.1 to 1.35), version 1.33 being used during the
major part of this period of the study. In-house precision
error on the scanner used, as determined from duplicate
examinations in ten healthy subjects, was 1.9% for total
body BMC. From January 2000, a LUNAR Prodigy
scanner (Scanex) was used. Software versions were
upgraded several times during data collection, from
version 5.70 to 8.10. The precision of the scanner was
estimated from repeated measurements on different
days in 30 subjects with coefﬁcients of variation (CV) of
total body BMC of 1.4%. Before the change of scanner in
2000, 31 subjects (19 males and 12 females), ranging
in weight from 51 to 112 kg, were scanned on both
scanners on the same day. Total body BMD was not
signiﬁcantly different between scanners (mean
difference, 0.019 g/cm
2; 95% conﬁdence interval for
the difference, K0.0079 to 0.00458 g/cm
2).
Daily quality control was performed according to
the manufacturer’s protocol. A spine phantom was
measured at least once a week. Every single spine
phantom measurement was compared with a baseline
value based on a mean of ten repeated measurements.
A maximum 1.5% deviation from the baseline value
was accepted. A European phantom (COMAC-BME
Quantitative Assessment of Osteoporosis Study Group)
was measured once a year. BMD z-score, which is the
difference in S.D. of age- and sex-matched healthy
subjects, and t-score, which is the difference in S.D.o f
sex-matched young (20–39 years) healthy subjects,
were determined using the Lunar DPX-L Software
program. The reference database used was the LUNAR
USA reference population for the region examined.
Biochemical analysis
Serum IGF1 concentration, until June 2004, was
determined using a hydrochloric acid–ethanol extrac-
tion RIA (Nichols Institute Diagnostics, San Juan
Capistrano, CA, USA). Inter- and intra-assay CV were
5.4 and 6.9% respectively, at a mean serum IGF1 level of
126 mg/l, and 4.6 and 4.7% respectively, at a mean
serum IGF1 level of 327 mg/l. From June 2004 to
August 2006, serum IGF1 concentration
was determined using a chemiluminescence immu-
noassay (Nichols Advantage; Nichols Institute
Diagnostics) (24). From September 2006, serum IGF1
level was determined using an automated chemi-
luminescent assay system (IMMULITE 2500, Diagnostic
Products Corp., Los Angeles, CA, USA). The standard
used for calibration of the IGF1 assays was the WHO
NIBSC 1st IRR 87/518 throughout the study period.
The individual serum IGF1 values were compared
with age- and sex-adjusted values obtained from a
reference population (25), and the individual IGF1
SDSs, taking into account age and gender, were then
calculated (26).
Statistical methods
All the descriptive statistical results are presented
as the mean and S.E.M. For all variables, within-group
differences were calculated using a repeated measures
ANOVA, with all data obtained from all time points,
and with time as the independent variable. Post hoc
analysis was performed using Student–Newman–Keuls
test. Gender differences and differences between
women on oestrogen replacement and women without
oestrogen replacement were calculated by a two-way
ANOVA, with all data obtained from all time points,
and with gender or oestrogen treatment as the
independent variables. In order to eliminate the baseline
differences, data were transformed into percent change
or change from baseline before the between-group
analyses. All analyses were performed according to
the intention-to-treat principle (using the carry forward
principle). A two-tailed P!0.05 was considered
signiﬁcant.
Results
GH dose and serum IGF1
The dose of GH prescribed at the baseline visit was
0.63 (0.03) mg/day (Table 3). The dose was then
gradually reduced to 0.41 (0.01) mg/day at study
end. Serum IGF1 levels increased during the ﬁrst
years of the study and then decreased to some extent.
Mean IGF1 SDS (adjustment for age and gender) was
above the normal range during the ﬁrst 3 years of the
study, but after that, it was within the normal range
(G2 S.D.).
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Mean body height decreased from 171.8 (0.94) cm at
baseline to 171.3 (0.97) cm after 15 years (P!0.001;
data not shown). Mean body weight increased from
81.5 (1.5) to 83.7 (1.5) kg (P!0.001) and BMI
increased from 27.6 (0.44) kg/m
2 at baseline to 28.5
(0.44) kg/m
2 at the end of the study (P!0.001).
BMC and BMD
GH replacement gradually increased total body BMC
during the ﬁrst 5 years of treatment as measured using
DXA (Table 4). Thereafter, total body BMC increased
slowly throughout the study period. After 15 years,
mean total body BMC was 5% above the baseline value
(P!0.001). Total body BMD had increased by 2% after
10 years (P!0.001 vs baseline) and then reached
a plateau. Total body t-score, after an initial decrease,
increased up to 10 years and then stayed at a constant
level. Total body z-score tended to decrease during the
ﬁrst 5 years of treatment and then increased during the
remaining part of the study.
Lumbar (L2–L4) spine BMC increased throughout the
studyperiodandwas9%abovethebaselinevalueafter15
yearsofGHreplacement(P!0.001vsbaseline;Table4).
Lumbar (L2–L4) spine BMD and t-score increased up to
10 years of GH treatment and remained at a constant
level between 10 and 15 years. After 15 years, lumbar
(L2–L4) spine BMD was 5% above the baseline value
(P!0.001 vs baseline). Lumbar (L2–L4) spine z-score
increased progressively throughout the study period.
Femur neck BMC reached a maximum level of 7%
above baseline (P!0.001) after 7 years (Table 4). After
that, femur neck BMC decreased and was 5% above
the baseline value after 15 years (P!0.01). Femur neck
BMDincreasedtoa maximum levelof3% above baseline
after 7 years of treatment (P!0.001). Femur neck BMD
thendecreasedandreturnedtothebaselinelevelafter15
years. Femur neck z-score reached a maximum after 7
years and then decreased but remained signiﬁcantly
elevated over the baseline level after 15 years.
Table 3 The dose of GH during 15 years of GH replacement in 126 GH-deﬁcient adults and the effects of this treatment on serum IGF1
concentration and IGF1 SDS. All values are shown as the mean (S.E.M.). The statistical analyses are based on a one-way ANOVA followed
by Student–Newman–Keuls post hoc test.
Baseline 3 years 5 years 7 years 10 years 12 years 15 years
P value
(10–15 years)
Dose of GH (mg/day) 0.63 (0.03) 0.51 (0.02)
‡ 0.49 (0.02)
‡ 0.46 (0.02)
‡ 0.44 (0.02)
‡ 0.42 (0.02)
‡ 0.41 (0.01)
‡ !0.001
Serum IGF1 (mg/l) 103 (6) 298 (10)
‡ 273 (10)
‡ 246 (8)
‡ 206 (8)
‡ 188 (7)
‡ 183 (7)
‡ !0.001
IGF1 SDS K1.69 (0.11) 2.28 (0.21)
‡ 1.89 (0.21)
‡ 1.47 (0.18)
‡ 0.84 (0.17)
‡ 0.56 (0.16)
‡ 0.62 (0.16)
‡ !0.05
P values (10–15 years) are based on the statistical analysis between the 10- and 15-year values. NS, non-signiﬁcant.
‡P!0.001 (for the dose of GH vs initial
GH dose; for other variables vs baseline).
Table 4 Effects of 15 years of GH replacement in 126 adults with GH deﬁciency on BMC, BMD, z-score and t-score as measured using
DXA. All values are shown as the mean (S.E.M.). The statistical analyses are based on a repeated measures ANOVA followed by Student–
Newman–Keuls post hoc test.
Baseline
(nZ126)
3 years
(nZ120)
5 years
(nZ112)
7 years
(nZ111)
10 years
(nZ103)
12 years
(nZ98)
15 years
(nZ90)
P value
(10–15 years)
DXA total body
BMC (kg) 2.73 (0.06) 2.77 (0.06) 2.81 (0.06)* 2.83 (0.06)
† 2.83 (0.07)
‡ 2.83 (0.07)
‡ 2.87 (0.07)
‡ NS
BMD (g/cm
2) 1.17 (0.01) 1.16 (0.01) 1.16 (0.01) 1.17 (0.01) 1.19 (0.01)
† 1.19 (0.02)
‡ 1.19 (0.02)
‡ NS
t-Score (S.D.) K0.05 (0.13) K0.19 (0.14) K0.18 (0.14)* 0.04 (0.15) 0.19 (0.16)
† 0.22 (0.17)
‡ 0.19 (0.17)
† NS
z-Score (S.D.) K0.11 (0.11) K0.20 (0.10) K0.19 (0.11) 0.06 (0.11)* 0.36 (0.13)
‡ 0.43 (0.14)
‡ 0.42 (0.13)
‡ NS
DXA lumbar (L2–L4) spine
BMC (g) 55.5 (1.5) 58.1 (1.7)
‡ 59.1 (1.8)
‡ 59.5 (1.8)
‡ 60.3 (1.9)
‡ 60.3 (1.9)
‡ 60.7 (2.0)
‡ NS
BMD (g/cm
2) 1.17 (0.02) 1.20 (0.02)
‡ 1.22 (0.02)
‡ 1.22 (0.02)
‡ 1.24 (0.02)
‡ 1.23 (0.02)
‡ 1.23 (0.02)
‡ NS
t-Score (S.D.) K0.44 (0.15) K0.13 (0.17)
‡ 0.03 (0.18)
‡ 0.06 (0.18)
‡ 0.19 (0.20)
‡ 0.13 (0.20)
‡ 0.18 (0.21)
‡ NS
z-Score (S.D.) K0.01 (0.14) 0.19 (0.14) 0.35 (0.15)
‡ 0.39 (0.16)
‡ 0.63 (0.18)
‡ 0.62 (0.18)
‡ 0.77 (0.19)
‡ 0.01
DXA femur neck
BMC (g) 4.87 (0.14) 5.04 (0.14) 5.14 (0.12)
† 5.20 (0.12)
‡ 5.15 (0.12)
† 5.13 (0.13)
† 5.12 (0.13)
† NS
BMD (g/cm
2) 0.94 (0.01) 0.96 (0.01)* 0.96 (0.02)
† 0.97 (0.02)
‡ 0.96 (0.02) 0.95 (0.02) 0.94 (0.02) !0.001
t-Score (S.D.) K0.71 (0.12) K0.45 (0.14)
† K0.49 (0.11)* K0.45 (0.12)
† K0.52 (0.12)* K0.63 (0.12) K0.75 (0.12) !0.001
z-Score (S.D.) K0.23 (0.10) 0.10 (0.12)
‡ 0.17 (0.10)
‡ 0.24 (0.10)
‡ 0.24 (0.10)
‡ 0.18 (0.11)
‡ 0.15 (0.11)
‡ !0.05
P values (10–15 years) are based on the statistical analysis between the 10- and 15-year values. NS, non-signiﬁcant;n, number of patients on GH replacement
at different time points; however, all 126 patients were included in the statistical analysis according to the intention-to-treat approach used. A separate analysis
of the patients (nZ90) who completed the 15 years of GH replacement showed approximately similar results (data not shown). *P!0.05;
†P!0.01;
‡P!0.001
vs baseline.
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Except for the initial dose of GH, women received
a higher dose of GH than men (P!0.001). The mean
initial GH dose was 0.71 (0.04) mg/day for men and
0.53 (0.04) mg/day for women whereas at study end,
the mean GH dose was 0.38 (0.02) mg/day for men and
0.45 (0.03) mg/day for women (P!0.05). IGF1 SDS
increased from K1.46 (0.14) at baseline to 0.27 after
15 years of GH replacement in men and from K1.98
(0.16) to 1.10 (0.22) in women (P!0.01 men vs
women; Fig. 1). Men had, however, a greater increase
than women in BMD at all skeletal locations measured
(Fig. 1). Similar gender differences, with men being
more responsive, were seen for BMC, t-scores and
z-scores except for femur neck BMC, where there was
no signiﬁcant gender difference (data not shown).
Women on oestrogen replacement vs women
without oestrogen replacement
Forty-eight of the 54 included women were gonado-
trophin deﬁcient. Twenty-ﬁve (52%) women at the
initiation of the study and 15 (31%) at the study end
received oestrogen replacement therapy. The reason for
fewer women receiving oestrogen replacement at study
end compared with baseline was discontinuation
because of age. The women receiving oestrogen
replacement at baseline were signiﬁcantly younger
(mean age 44.5 (2.1) years) than the women without
oestrogen therapy (mean age 57.5 (2.2) years,
P!0.001). Women on oestrogen replacement therapy
received a signiﬁcantly higher dose of GH than women
without oestrogen replacement (P!0.001). There was
no difference in serum IGF1 level or IGF1 SDS between
women with and without oestrogen replacement. There
was also no difference in treatment response in BMD
or BMC at any skeletal site measured.
Osteopenia and osteoporosis
At baseline, 37.8 and 38.8% of the patients had osteo-
penia (t-score !K1.0 S.D.) in the lumbar (L2–L4) spine
and femur neck respectively (Table 5). After 15 years of
GH replacement, 30.6% of the patients had osteopenia
in the lumbar (L2–L4) spine and 40.8% in the femur
neck (Table 5). The patients with remaining osteopenia
at study end, as measured in the femur neck, were older
(mean age 67.6 (1.7) vs 62.4 (1.5) years respectively,
P!0.05) and included a larger proportion of women
(61.1 vs 38.7% respectively). Among the patients with
osteopenia in the lumbar (L2–L4) spine after 15 years of
GH replacement, 69.0% were women compared with
37.7% women among patients without osteopenia, but
there was no age difference.
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Figure 1 The gender differences in the effects of 15 years of GH
replacement in 126 GH-deﬁcient adults on IGF1 SDS (A) and BMD
in total body (B), lumbar (L2–L4) spine (C) and femur neck (D).
IGF1 SDS are shown as S.D. for men and women. The grey
rectangle shows the normal range of K2t oC2 S.D. The results in
BMDareshown aspercentchangefrombaseline.Theverticalbars
indicate the S.E.M. values shown. P values for men vs women are
basedonatwo-wayANOVAofthepercentchangefrombaselinein
each group. *P!0.05; ***P!0.001 vs baseline.
Table 5 Osteopenia (t-score !K1.0 S.D.) and osteoporosis(t-score !K2.5 S.D.) at baseline and after 15 years of GH replacementtherapy
in 126 GH-deﬁcient adults. Patients with an increase in t-score of O0.5 were arbitrarily considered to have an increase in t-score. Likewise,
patients with a decrease in t-score of O0.5 were considered to have a decrease in t-score and patients with an increase or decrease in
t-score of !0.5 were considered to have an unchanged t-score.
Baseline (%) After 15 years (%)
Osteopenia
(t-score
!K1.0 S.D.)
Osteoporosis
(t-score
!K2.5 S.D.) Increased Unchanged Decreased
Osteopenia
(t-score
!K1.0 S.D.)
Osteoporosis
(t-score
!K2.5 S.D.)
Total body 23.5 5.1 43.9 33.7 22.4 24.5 6.1
Lumbar (L2–L4)
spine
37.8 9.2 50.0 34.7 15.3 30.6 11.2
Femur neck 38.8 7.1 24.5 46.9 28.6 40.8 7.1
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responded to the 15 years of GH replacement in terms
of t-scores is summarised in Table 5. Furthermore, the
percentage of patients with normal BMD corrected for
age and gender (z-score O0) are shown in Fig. 2.
Fractures
No fractures were reported in men. One woman suffered
from a hip fracture and one woman had a symptomatic
vertebral fracture, both after 7 years of GH replacement.
X-ray examinations were not performed to determine
asymptomatic vertebral fractures. No patient had
a height loss of O5 cm whereas two men and four
women had a height loss of 3–4.5 cm.
Correlation
Baseline femur neck BMC correlated inversely with the
percent change in the same variable (rZK0.47,
P!0.001). This indicates that those patients with the
lowest femur neck BMC at baseline had the greatest
increase in this variable after 15 years of GH
replacement. There was no correlation between the
baseline value and the percent change in any other
variable reﬂecting bone mass and density.
At baseline, there were positive correlations between
serum IGF1 and total body BMC (rZ0.31, P!0.01)
and BMD (rZ0.35, P!0.001), lumbar (L2–L4) spine
BMC (rZ0.24, P!0.05) and BMD (rZ0.26, P!0.01),
and femur neck BMC (rZ0.26, PZ0.01) and BMD
(rZ0.30, P!0.01).
The percent change in serum IGF1 correlated
positively with the percent change in femur neck
BMC (rZ0.25, PZ0.01), indicating that those patients
with the highest increase in serum IGF1 had the
greatest treatment response in terms of femur neck
BMC. No correlation was seen at study end between the
percent change in serum IGF1 and the percent change
in BMC or BMD at other skeletal sites.
There was no correlation between the GH dose at
study end and the percent change in any of the DXA
variables measured.
Discussion
This single-centre study is the longest and one of the
largest studies of the effects of GH replacement therapy
in patients with AO GHD on bone mass and density. The
results show that 15 years of GH replacement induced a
sustained increase in total body and lumbar (L2–L4)
spine BMC and BMD. At study end, all z-scores were
normalised (above zero).
Total body and lumbar (L2–L4) spine BMC, BMD,
t-score and z-score values were signiﬁcantly above the
baseline levels after 15 years of GH replacement.
The main increase occurred during the ﬁrst 7–10
years. The results of previous studies suggest, taken
together, that GH replacement increases BMC and BMD
during the ﬁrst 5–10 years of therapy, whereas after
that a plateau is reached in the absolute values of BMC
and BMD (13, 15, 19, 20, 22). There are no previous
studies over a longer period than 10 years. In this study,
no further gain in absolute values of total body and
lumbar (L2–L4) spine BMC and BMD occurred between
10 and 15 years of GH replacement. However, lumbar
(L2–L4) spine z-score was increased at 15 years
compared with the 10-year value. In the femur neck,
the response to 15 years of GH replacement was
different compared with the responses in total body
and lumbar (L2–L4) spine. Femur neck BMC and BMD
increased to a maximum after 7 years and then started
to decrease. After 15 years, femur neck BMD and t-score
had returned to the baseline value.
The reason why bone mass and density decreased
between 10 and 15 years of GH replacement in the
femur neck and not in the lumbar spine is not fullyclear.
Femur neck is composed of more cortical bone whereas
lumbar spine is composed of more trabecular bone (27).
It is well known that the trabecular bone in the lumbar
spine is sensitive to sex steroids, which is noticed for
instance in postmenopausal women (27). In the femur
neck, with predominantly cortical bone, BMD decreases
with increasing age resulting in senile osteoporosis,
which affects both elderly men and women (27).I ti s
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Figure 2 The percentage of patients with normal BMD adjusted for
age, i.e. z-score O0, in total body (A), lumbar (L2–L4) spine (B) and
femur neck (C) during 15 years of GH replacement to 126 adults
with GH deﬁciency. In all locations, the percentage of patients with
z-score O0 increased throughout the study period.
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in this study contributed to the increase in bone density
at lumbar (L2–L4) spine whereas it had only a lesser
effect on bone mass in femur neck. Furthermore, the
dose of GH was gradually reduced during the study
period and the possibility cannot be excluded that the
dose of GH used at studyend was not sufﬁciently high to
maintain the increase in femur neck bone mass and
density. In some support of this assumption, the percent
change in serum IGF1 correlated positively with the
percent change in femur neck BMC after 15 years,
indicating that the patients with the highest increase
in serum IGF1, and therefore likely the highest dose
of GH, had the greatest treatment response in terms of
femur neck BMC.
In all variables at all skeletal sites, except for femur
neck BMC, men had a greater treatment response to GH
replacement than women. Similar gender differences
in responsiveness have been observed in several
previous studies (13, 15, 16, 18, 19). The mechanisms
underlying these gender differences are not fully
understood, but sex hormones might play a role (19).
In terms of oestrogens, there was no difference in the
treatment responses in BMD or BMC at any skeletal site
measured between gonadotrophin-deﬁcient women
receiving or not receiving oestrogen replacement at
baseline. However, a smaller number of women received
oestrogen replacement at study end (nZ15) than at
baseline (nZ25), which could have contributed to
t h el a c ko fd i f f e r e n c eb e t w e e nw o m e nw i t ha n d
without oestrogen therapy. Further studies are therefore
needed to clarify the importance of oestrogen replace-
ment during long-term GH replacement. Moreover,
androgens may interact with GH, resulting in increased
bone mass (19). The possibility cannot be excluded
that the testosterone replacement contributed to
increased bone mass and density in the GHD men,
although this could not be evaluated in more detail as
most men were gonadotrophin deﬁcient and all
gonadotrophin-deﬁcient men received testosterone
replacement.
A main question is whether GH replacement reduces
the risk of fractures. Patients with GHD that do not
receive GH replacement have an increased risk of
fractures (8, 9, 10). There are some indications that
GH replacement can reduce the incidence of fractures
(10, 28). Although increased number of falls due to
visual impairment caused by pituitary tumours or their
treatment could be of importance, BMD t-score has been
shown as an important predictor of fracture risk (29,
30). Therefore, an increase in bone mass and density,
and especially BMD t-score, probably means that
15 years of GH replacement can reduce the fracture
risk in GHD patients. Two fractures were reported in this
study: one hip fracture and one symptomatic vertebral
fracture. X-ray examinations were not performed to
determine asymptomatic vertebral fractures. However,
it has been estimated that two-thirds to three-quarters
of vertebral fractures are asymptomatic and therefore
remain undiagnosed (31). Patients with vertebral
fractures have a mean height loss of around 5 cm (32,
33). No patient in our study had a height loss of 5 cm or
more whereas six patients (two men) had a height loss
of 3–4.5 cm. Therefore, we cannot exclude the possi-
bility that a few of the GHD patients included in this
study had asymptomatic vertebral fractures. Further-
more, this study is too small to evaluate fracture
incidence. This would need large, probably multi-centre
studies because GHD is a relatively rare condition and
most centres do not have enough patients to evaluate
the risk of fractures.
A limitation of the study is the lack of a control
group. For ethical reasons, the study cannot be made
with a control group of GHD patients without GH
replacement. The use of t-scores and z-scores may to
some extent compensate for the lack of a longitudinal
control group. At the end of 1999, the DXA machine
used was changed. The new DXA was, however,
calibrated to show as similar values as possible
compared with the old DXA. In terms of t-scores
and z-scores, the LUNAR USA reference population
was used as the reference database throughout the
study period. Furthermore, the level of physical
activity was not recorded. However, no effort was
made to inﬂuence the patients’ physical activity level
during the study period. Another limitation of the
study is that the IGF1 assay was changed two times.
Although the WHO NIBSC 1st IRR 87/518 standard
was used for calibration throughout the study period,
it cannot be excluded that the changes in IGF1 assay
could have inﬂuenced the results of the IGF1
measurements. Finally, all patients were retained in
the statistical analysis according to the intention-
to-treat principle used. A separate analysis of the
patients (nZ90) who completed the 15 years of
GH replacement was made and showed similar results
(data not shown).
In conclusion, this study shows that 15 years of
GH replacement to GHD adults induces a sustained
increase in total body and lumbar (L2–L4) spine BMD
and BMC. Femur neck BMC and BMD peaked after
7 years of treatment and then decreased towards
baseline values, which might be due to the mean GH
dose being relatively low during the last years of the
study. Our study is the ﬁrst that has studied the effect of
15 years of GH replacement and the results give further
support to the usefulness of long-term GH replacement
to GHD adults. It remains to be investigated in studies
larger than the present one whether 15 years of GH
replacement reduce the risk of fractures. Men had
a greater treatment response than women despite
women receiving a higher dose of GH. Further studies
that look in more detail into the effect of sex hormones
are needed to clarify the mechanisms behind these
gender differences.
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